LABORATORIO REIG JOFRE S.A. financials
LABORATORIO REIG JOFRE S.A.
Country: ES Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
9598003MRMJHA81QJF20 Financial statements
(EUR, as reported — unscaled; 120 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €338.9M | €316.1M |
| Employee benefits expense | €87.7M | €75.9M |
| Raw materials & consumables used | €142.1M | €140.5M |
| Depreciation & amortisation | €23.4M | €23.1M |
| Operating profit (EBIT) | €12.6M | €10.5M |
| Net finance income / (cost) | -€671.0K | -€998.0K |
| Finance costs | €2.0M | €1.2M |
| Profit before tax | €11.8M | €10.5M |
| Income tax expense | €1.4M | €1.1M |
| Profit for the year | €10.5M | €9.4M |
| — attributable to owners | €10.4M | €9.4M |
| — attributable to NCI | €85.0K | -€10.0K |
| Total comprehensive income | €10.3M | €9.8M |
| Per share | ||
| Basic EPS | €0.13 | €0.12 |
| Diluted EPS | €0.13 | €0.12 |
| Free cash flow / share | €0.14 | €0.08 |
| Cash flow statement | ||
| Net cash from operating activities | €31.3M | €19.1M |
| Net cash from investing activities | -€32.0M | -€12.9M |
| Purchase of PP&E (capex) | €20.3M | €12.5M |
| Purchase of intangibles | €519.0K | €307.0K |
| Net cash from financing activities | €5.6M | -€7.2M |
| Dividends paid | €25.0K | €41.0K |
| Proceeds from borrowings | €32.9M | €10.2M |
| Repayments of borrowings | €28.4M | €18.0M |
| Balance sheet | ||
| Total assets | €344.9M | €330.5M |
| Non-current assets | €195.2M | €198.0M |
| Property, plant & equipment | €97.0M | €91.6M |
| Intangible assets & goodwill | €26.8M | €28.0M |
| Current assets | €149.7M | €132.6M |
| Inventories | €63.8M | €61.9M |
| Trade & other receivables | €56.0M | €55.9M |
| Cash & equivalents | €10.5M | €5.5M |
| Total equity | €213.9M | €204.3M |
| — attributable to owners | €214.0M | €204.4M |
| Non-controlling interests | -€18.0K | -€97.0K |
| Non-current liabilities | €48.8M | €36.1M |
| Lease liabilities (non-current) | €7.2M | €9.9M |
| Current liabilities | €82.1M | €90.2M |
| Lease liabilities (current) | €5.3M | €4.9M |
| Trade & other payables | €44.9M | €47.7M |
| Deferred tax liabilities | €2.4M | €2.6M |
| Derived metrics | ||
| Free cash flow | €11.1M | €6.7M |
| Operating margin | 3.7% | 3.3% |
| Net margin | 3.1% | 3.0% |
| Return on equity | 4.9% | 4.6% |
| Cash conversion ratio | 2.99× | 2.03× |
| Capex coverage | 1.55× | 1.53× |
| Other reported items | ||
| Accumulated Other Comprehensive Income | -€32.0K | -€105.0K |
| Adjustments For Decrease Increase In Inventories | -€2.1M | -€13.9M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -€1.2M | -€4.7M |
| Adjustments For Depreciation and Amortisation Expense | €23.4M | €23.1M |
| Adjustments For Finance Costs | €2.0M | €1.2M |
| Adjustments For Finance Income | -€287.0K | -€63.0K |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | €1.4M | €716.0K |
| Adjustments For Gains Losses On Change In Fair Value of Derivatives | -€994.0K | -€104.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Inventories | €162.0K | €246.0K |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Property Plant and Equipment | €1.0M | €1.0M |
| Adjustments For Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss Trade and Other Receivables | €362.0K | -€152.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€254.0K | €6.9M |
| Adjustments For Provisions | €20.0K | €10.0K |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | €117.0K | -€984.0K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -€13.0K | -€72.0K |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €6.6M | €0 |
| Changes In Equity | -€559.0K | -€102.0K |
| Changes In Inventories of Finished Goods and Work In Progress | -€1.9M | -€6.7M |
| Comprehensive Income Attributable To Noncontrolling Interests | €85.0K | -€10.0K |
| Comprehensive Income Attributable To Owners of Parent | €10.2M | €9.8M |
| Current Contract Liabilities | €5.1M | €4.9M |
| Current Financial Liabilities | €3.4M | €3.5M |
| Current Loans Received and Current Portion of Noncurrent Loans Received | €16.2M | €25.2M |
| Current Tax Assets Current | €5.0M | €6.0M |
| Current Tax Liabilities Current | €7.1M | €3.6M |
| Deferred Tax Assets | €9.0M | €8.9M |
| Dividends Recognised As Distributions To Owners Per Share | €25000.00 | — |
| Equity and Liabilities | €344.9M | €330.5M |
| Fair Value of Investments In Equity Instruments Designated As Measured At Fair Value Through Other Comprehensive Income | €961.0K | €1.4M |
| Finance Income | €287.0K | €63.0K |
| Gains Losses On Change In Fair Value of Derivatives | €994.0K | €104.0K |
| Gains Losses On Exchange Differences On Translation Before Tax | -€285.0K | €384.0K |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | €13.0K | €72.0K |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €2.4M | €1.7M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | €24.0K | €7.0K |
| Income Taxes Paid Refund Classified As Operating Activities | -€289.0K | €1.5M |
| Increase Decrease In Cash and Cash Equivalents | €5.0M | -€928.0K |
| Increase Decrease Through Appropriation of Retained Earnings | -€6.0K | -€6.0K |
| Increase Decrease Through Sharebased Payment Transactions | €86.0K | -€41.0K |
| Increase Decrease Through Transfers and Other Changes Equity | -€611.0K | €6.0K |
| Increase Decrease Through Treasury Share Transactions | -€3.0K | -€20.0K |
| Intangible Assets Other Than Goodwill | €55.3M | €63.1M |
| Interest Paid Classified As Financing Activities | €25.0K | €41.0K |
| Interest Paid Classified As Operating Activities | €2.0M | €1.2M |
| Interest Received Classified As Operating Activities | €275.0K | €63.0K |
| Investments In Associates Accounted For Using Equity Method | €5.6M | €4.6M |
| Issue of Equity | €0 | €0 |
| Issued Capital | €40.4M | €39.8M |
| Miscellaneous Other Operating Expense | €76.4M | €73.7M |
| Miscellaneous Other Operating Income | €1.0M | €547.0K |
| Noncurrent Government Grants | €3.6M | €3.6M |
| Noncurrent Portion of Noncurrent Loans Received | €29.9M | €13.5M |
| Other Adjustments To Reconcile Profit Loss | -€2.4M | -€1.9M |
| Other Comprehensive Income | -€212.0K | €406.0K |
| Other Current Assets | €1.9M | €2.3M |
| Other Current Financial Assets | €12.5M | €964.0K |
| Other Current Liabilities | €275.0K | €390.0K |
| Other Financial Liabilities | €5.4M | €6.3M |
| Other Inflows Outflows of Cash Classified As Operating Activities | €41.0K | €213.0K |
| Other Noncurrent Financial Assets | €462.0K | €410.0K |
| Other Reserves | €149.1M | €140.9M |
| Other Work Performed By Entity and Capitalised | €2.5M | €1.9M |
| Payments To Acquire Or Redeem Entitys Shares | €3.0K | €20.0K |
| Proceeds From Government Grants Classified As Financing Activities | €1.2M | €666.0K |
| Proceeds From Other Longterm Assets Classified As Investing Activities | €391.0K | €226.0K |
| Profit Loss From Continuing Operations | €10.5M | €9.4M |
| Provisions | €225.0K | €199.0K |
| Purchase of Other Longterm Assets Classified As Investing Activities | €5.0M | €336.0K |
| Reserve of Exchange Differences On Translation | -€2.3M | -€2.0M |
| Revenue From Government Grants | €260.0K | €235.0K |
| Share of Profit Loss of Associates Accounted For Using Equity Method | -€117.0K | €984.0K |
| Share Premium | €19.0M | €19.0M |
| Treasury Shares | €2.9M | €2.8M |
Methodology
Every line item above is a fact tagged in LABORATORIO REIG JOFRE S.A.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.